Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: A study of the gynecologic oncology group of the comprehensive cancer center limburg

Anti-Cancer Drugs

Volumn 8, Issue 5, 1997, Pages 432-435

  Wils, J A ^a   Van Geuns, H ^b   Wals, J ^c   Vreeswijk, J ^b   Lalisang, F ^d  

^a LAURENTIUS HOSPITAL   (Netherlands)

^b Maartens Hospital   (Netherlands)

^c Gregorius Hospital   (Netherlands)

^d St Jans Hospital   (Netherlands)

Author keywords

Carboplatin; Growth factors; Ovarian cancer

Indexed keywords

ANTIEMETIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; EPIRUBICIN; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOPENIA; OVARY CANCER; PALLIATIVE THERAPY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030757254     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199706000-00003     Document Type: Article

References (11)

1. Wils JA. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxonibicin, and cyclophosphamide. Oncology 1990; 47: 115-20.
2. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-72.
3. Vermorken JB, Hoekman K. Chemotherapy for gynecologic malignancies. Curr Opin Oncol 1995; 7: 457-65.
4. Gersherson DM, Kavanagh JJ, Copeland LJ, et al. Retreatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 1989; 73: 798-802.
5. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
6. McGuire WP, Abelott MD. Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma - a world of caution (editorial). J Natl Cancer Inst 1989; 81: 1438-9.
7. Neijt JP. Ovarian cancer: rethinking prognostic factors and chemo-therapy. ASCO Educational Book 1994: 214-20.
8. Alberts DS, Canetta R, Mason-Liddil N. Carboplatin in the first-line chemotherapy of ovarian cancer. Semin Oncol 1990; 17 (suppl 2): 54-60.
9. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-67.
10. Ozols RF, Thigpen JT, Dauplat J, et al. Dose intensity. Ann Oncol 1993; 4 (suppl 4): 49-56.
11. De Vries EGE, Biesma B, Willemse PHB, et al. A double-blind placebo-controlled study with GM-CSF during chemotherapy for ovarian carcinoma. Cancer Res 1991; 51: 116-22.